Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries

Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.A vial of lenacapavir, an injectable H.I.V. prevention drug. A generic version will be sold in 120 countries, but a few large countries, which together account for 20 percent of new infections, will not have access to a low-cost version.